Nast A, et al. – The purpose of this study was to generate evidence with regard to the number of patients dropping out of etanercept trials over time, with the inclusion of Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) data. An improved effect was illustrated by a critical time when many patients possibly lost their willingness to wait for their treatment with etanercept, at around Day 80. Maximum patients dropping out exhibited minor improvement, stable disease or worsening of their psoriasis.